{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:30:46Z","timestamp":1734499846354,"version":"3.30.2"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.nefroe.2024.11.015","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T12:11:14Z","timestamp":1734437474000},"page":"796-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies"],"prefix":"10.1016","volume":"44","author":[{"given":"William","family":"Suciangto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haerani","family":"Rasyid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasya Angelica","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winny","family":"Suciangto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2024.11.015_bib0120","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0125","article-title":"Hyperphosphatemia and chronic kidney disease: a major daily concern both in adults and in children","author":"Bacchetta","year":"2020","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0130","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.kint.2017.11.036","article-title":"Prevention and treatment of hyperphosphatemia in chronic kidney disease","volume":"93","author":"Vervloet","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.jrn.2020.02.003","article-title":"Management of hyperphosphatemia in end-stage renal disease: a new paradigm","volume":"31","author":"Rastogi","year":"2021","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0140","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.ajkd.2020.05.025","article-title":"State-of-the-art management of hyperphosphatemia in patients with CKD: an NKF-KDOQI controversies perspective","volume":"77","author":"Scialla","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18773\/austprescr.2017.002","article-title":"Phosphate binders in patients with chronic kidney disease","volume":"40","author":"Chan","year":"2017","journal-title":"Aust Prescr"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/17512433.2020.1762570","article-title":"Tenapanor for the treatment of irritable bowel syndrome with constipation","volume":"13","author":"Sinagra","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/CEG.S384251","article-title":"Tenapanor in the treatment of irritable bowel syndrome with constipation: discovery, efficacy, and role in management","volume":"16","author":"Herekar","year":"2023","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0160","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1681\/ASN.2018080832","article-title":"Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial","volume":"30","author":"Block","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0165","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1681\/ASN.2016080855","article-title":"Effect of tenapanor on serum phosphate in patients receiving hemodialysis","volume":"28","author":"Block","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ekir.2021.11.008","article-title":"Dose\u2013response of tenapanor in patients with hyperphosphatemia undergoing hemodialysis in Japan \u2013 a phase 2 randomized trial","volume":"7","author":"Inaba","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0175","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ndt\/gfy061","article-title":"The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia","author":"Block","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0180","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1681\/ASN.2020101398","article-title":"A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY)","volume":"32","author":"Pergola","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0185","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1159\/000516156","article-title":"Therapeutic effects of add-on tenapanor for hemodialysis patients with refractory hyperphosphatemia","author":"Shigematsu","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0190","first-page":"1","article-title":"Randomized study of tenapanor added","author":"Nitta","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0195","first-page":"382","article-title":"2018 ACC\/AHA\/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhyth","volume":"140","author":"Kusumoto","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jamadermatol.2017.3647","article-title":"Effect of oral administration of a mixture of probiotic strains on SCORAD index and use of topical steroids in young patients with moderate atopic dermatitis a randomized clinical trial","volume":"154","author":"Navarro-Lopez","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0205","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.ekir.2021.05.012","article-title":"Phosphate balance and CKD \u2013 mineral bone disease","volume":"6","author":"Sprague","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu13051670","article-title":"The importance of phosphate control in chronic kidney disease","volume":"13","author":"Tsuchiya","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0215","first-page":"11","article-title":"Hyperphosphatemia","author":"Goyal","year":"2023","journal-title":"StatPearls NCBI Bookshelf"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0220","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2016.11.012","article-title":"Vascular calcification in CKD-MBD: roles for phosphate, FGF23, and klotho","volume":"100","author":"Yamada","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0225","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/sdi.12411","article-title":"Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease","volume":"28","author":"Felsenfeld","year":"2015","journal-title":"Semin Dial"},{"key":"10.1016\/j.nefroe.2024.11.015_bib0230","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.gastro.2022.04.016","article-title":"AGAclinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation","volume":"163","author":"Chang","year":"2022","journal-title":"Gastroenterology"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251424002189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251424002189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T12:11:22Z","timestamp":1734437482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251424002189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2013251424002189"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2024.11.015","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2024.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}